RAPT Therapeutics — Investor Presentation (December 2024)
21 slides from RAPT Therapeutics's investor presentation, Dec 23, 2024
Slide 1: Corporate Presentation
December 23, 2024 Corporate Presentation Exhibit 99.3
Slide 2: Disclaimer
Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development plans; current and future drug candidates, including the in-li
Slide 3: RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases
RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases RPT904 (JYB1904) is a half-life extended (HLE) anti-IgE omalizumab “bio-better” antibody licensed from Jemincare, a leading Chinese pharmaceutical company License terms: $35M upfront, ~$672M milestones, royalties of hig
Slide 4: Commercial Opportunity RPT904
Commercial Opportunity RPT904
Slide 5: Omalizumab is Highly Efficacious in Food Allergy
Omalizumab is Highly Efficacious in Food Allergy Active across multiple common food allergens Dosing at Q2W/Q4W based on FA dosing table OUTMATCH Wood et al. NEJM 2024
Slide 6: Omalizumab is an Emerging Blockbuster in Food Allergy
Omalizumab is an Emerging Blockbuster in Food Allergy According to Roche, 17M pts in the US → ~50% have severe reactions → ~30K ER visits/year† Omalizumab is the first and only FDA-approved therapy to reduce allergic reactions to multiple foods, based on Phase 3 OUtMATCH study Rapid launch in FA: 30
Slide 7: High Unmet Need and Large Commercial Opportunity in Food Allergy (FA)
High Unmet Need and Large Commercial Opportunity in Food Allergy (FA) Treatment environment is dominated by inconvenient treatments with room to improve compliance and efficacy Food avoidance and single allergen desensitization (e.g. oral immunotherapy) Rapid uptake of omalizumab demonstrates high u
Slide 8: CSU Offers an Additional Commercial Opportunity
CSU Offers an Additional Commercial Opportunity CSU affects >1M patients in the US(1) Antihistamines are first treatment step, but ~400k patients not controlled on antihistamines(2) Omalizumab is only approved biologic for CSU after failure of antihistamines RPT904 positioned to be preferred choice
Slide 9: A Potential Best-in-Class Anti-IgE mAb RPT904
A Potential Best-in-Class Anti-IgE mAb RPT904
Slide 10: RPT904 is a Potential Best-in-Class Omalizumab Bio-better mAb
RPT904 is a Potential Best-in-Class Omalizumab Bio-better mAb RPT904 is a half-life extended (HLE) anti-IgE monoclonal antibody with improved potency Incorporates proven HLE technology using the YTE mutation Q8W/Q12W dosing versus Q2W/Q4W with omalizumab Uses clinically validated epitope identical t
Slide 11: RPT904: Minimally Altered to Optimize Dosing Frequency While Targeting Clinically Validated Epitope
RPT904: Minimally Altered to Optimize Dosing Frequency While Targeting Clinically Validated Epitope Omalizumab as starting point Retains clinically validated epitope YTE mutation: >2-fold half-life extension over omalizumab Additional conservative improvements Affinity maturation: ~4-fold affinity o
Slide 12: Phase 1 Healthy Volunteer Data and Dose Estimations RPT904
Phase 1 Healthy Volunteer Data and Dose Estimations RPT904
Slide 13: Design of Jemincare Phase 1 Healthy Volunteer Study
Design of Jemincare Phase 1 Healthy Volunteer Study
Slide 14: Phase 1 Trial of RPT904 Shows a Longer Half-Life and Superior IgE Reduction Compared to Omalizumab
Phase 1 Trial of RPT904 Shows a Longer Half-Life and Superior IgE Reduction Compared to Omalizumab At 150 mg, half life for RPT904 was 63 Days vs. 27 days for omalizumab Superior free IgE reduction relative to omalizumab Due to non-standard free-IgE assay format, PD comparisons of absolute free-IgE
Slide 15: IgE Pharmacodynamic Simulations Support Q12W Dosing In Most Patients
IgE Pharmacodynamic Simulations Support Q12W Dosing In Most Patients 20 kg at 700 IU/ml IgE represents median IgE and estimated median weight in the Phase 3 OMA FA trial Omalizumab 225 mg Q4W is approved dose RPT904 at 300 mg Q12W achieves target IgE Levels *Target free IgE of 25 ng/ml ensures ≥ 95%
Slide 16: Phase 2 Trial Designs RPT904
Phase 2 Trial Designs RPT904
Slide 17: Proposed Phase 2b Randomized Double-Blind Placebo-Controlled Study of RPT904 in Food Allergy
RPT904 Q12W regimen (N=30) Primary Endpoint: DBPCFC N=75 (2:2:1 Q12W, Q8W regimens and placebo) US/European clinical sites ~18 months from FPI to topline data Proposed Phase 2b Randomized Double-Blind Placebo-Controlled Study of RPT904 Monotherapy in Food Allergy Children and Adults (Start in ages 1
Slide 18: Phase 2b FA Simplified Dosing Regimens Cover Entire Omalizumab Dosing Table
Phase 2b FA Simplified Dosing Regimens Cover Entire Omalizumab Dosing Table Randomization Illustrative simplified dosing table based on baseline IgE and weight 3 dose strengths compared to omalizumab’s 8 dose strengths Plan is to also include patients currently excluded from OMA label Additional PK/
Slide 19: Jemincare Phase 2 Asthma and CSU Clinical Development Plan
Jemincare Phase 2 Asthma and CSU Clinical Development Plan
Slide 20: RPT904 Anticipated Milestones
RPT904 Anticipated Milestones 1H 2025 2H 2025 1H 2026 2H 2026 1H 2027 2H 2027 FA Phase 2b Start (US/Europe) FA Phase 2b Topline Data CSU Phase 2b or 3 Start (US/Europe) JYB1904 Asthma Topline Data (China) 1st IND Filing JYB1904 CSU Topline Data (China) PK/PD HV PK/PD Atopic
Slide 21: Thank You
Thank You
RAPT Therapeutics — Investor Presentation (December 2024) on 6ix